3745350 Canada Inc (YMI:US)
was acquired by GILD:US
3745350 Canada Inc. is developing cancer drugs based on technologies licensed primarily from international academic centers. The Company is currently developing a small molecule chemopotentiator for metastatic breast cancer, an EGFr humanized monoclonal antibody, and a GnRH cancer vaccine. 3745350 Canada is also supporting the preclinical development of additional cancer products.